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Abstract
Background: This study assessed the postoperative morbidity and mortality occurring in the first 30 days after
radical gastrectomy by comparing gastric cancer patients who did or did not receive the FOLFOX7 regimen of
neoadjuvant chemotherapy.
Methods: We completed a retrospective analysis of 377 patients after their radical gastrectomies were performed
in our department between 2005 and 2009. Two groups of patients were studied: the SURG group received
surgical treatment immediately after diagnosis; the NACT underwent surgery after 2-6 cycles of neoadjuvant
chemotherapy.
Results: There were 267 patients in the SURG group and 110 patients in the NACT group. The NACT group had
more proximal tumours (P = 0.000), more total/proximal gastrectomies (P = 0.000) and longer operative time (P =
0.005) than the SURG group. Morbidity was 10.0% in the NACT patients and 17.2% in the SURG patients (P =
0.075). There were two cases of postoperative death, both in the SURG group (P = 1.000). No changes in
complications or mortality rate were observed between the SURG and NACT groups.
Conclusion: The FOLFOX7 neoadjuvant chemotherapy is not associated with increased postoperative morbidity,
indicating that the FOLFOX7 neoadjuvant chemotherapy is a safe choice for the treatment of local advanced
gastric cancer.
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Background
Long-term survival is the gold standard in the assess-
ment of gastric cancer. The complete surgical resection
of tumours with negative margins (R0 resection) has
been considered the most effective treatment for gastric
cancer and is associated with improved long-term survi-
val [1,2]. The concept of neoadjuvant chemotherapy has
recently been widely accepted to increase the R0 resec-
tion rate and the long-term survival in patients with gas-
tric cancer. To date, owing to the results of the Medical
Research Council Adjuvant Gastric Infusional Che-
motherapy (MAGIC) trial, perioperative chemotherapy
for locally advanced resectable gastric cancer has
become a grade A recommendation [3]. Although the
role of neoadjuvant therapy has now been established,
the optimal regimen remains to be determined. Various
regimens of neoadjuvant chemotherapy in gastric cancer
have been shown to induce tumour responses [4]. But
the potential accompanied disadvantages, including
increased surgical complications, cannot be ignored. In
addition, patients who may not be eligible to receive
postoperative adjuvant therapy because of poor perfor-
mance status secondary to postoperative complications
may benefit from receiving systemic therapy first. There
are limited data available regarding postoperative mor-
bidity and mortality in patients receiving neoadjuvant
chemotherapy for gastric cancer. If neoadjuvant che-
motherapy is to be considered as a therapeutic option in
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sary to verify that treatment can be delivered safely
without an increase in postoperative morbidity and
mortality.
Neoadjuvant chemotherapy with the FOLFOX regi-
men for local advanced gastric cancer has been per-
formed for years in our centre. The current
retrospective study was undertaken to assess the post-
operative morbidity and mortality in patients receiving
FOLFOX7 neoadjuvant chemotherapy prior to radical
gastrectomy for local advanced gastric cancer in com-
parison to patients who underwent gastrectomy alone
during the same time period, at the same institutions,
by the same surgeons.
Methods
Patients’ medical records and histologic data during the
period from April 18, 2005 to October 20, 2009 were
retrospectively studied. Patients included in the study
had histologically confirmed gastric adenocarcinomas
and received curative gastrectomy with D2 lymph node
dissection by the same surgeons at the department of
Surgery of the Beijing Cancer Hospital & Institute and
the Peking University School of Oncology. Of these,
there were 267 patients (SURG group) who received
surgical treatment immediately after diagnosis and
another 110 patients (NACT group) who first received
FOLFOX7 neoadjuvant chemotherapy. Information
regarding postoperative morbidity and mortality was
available for each patient studied. Mortality was defined
as a lethal outcome during the operation or within the
first 30 postoperative days. Complications were also
considered if they occurred in the same period. All
patients were diagnosed prior to therapy with resectable
local advanced gastric cancer as T3-4 N any and M0,
according to the 1997 American Joint Committee on
Cancer criteria (AJCC). All patients routinely underwent
chest and abdominal CT and laparoscopy for staging
purposes and must have had measurable disease to
enable response monitoring. Endoscopic ultrasound
(EUS) was also performed for patients in the neoadju-
vant arm of the study. Patients were allocated to either
of the treatment arms based on patient preference after
the pros and con of each treatment modality were fully
explained using a standard pro forma. Patients who
required urgent surgery for obstruction, perforation, or
bleeding and patients who did not receive radical gas-
trectomy were not included in this study. Induction che-
motherapy with 2 to 6 cycles of FOLFOX7 was
completed on an outpatient basis, which consisted of a
2-hour infusion of folinic acid at 400 mg/m
2 followed
by a 5-FU 46-hour infusion of 2,400 mg/m
2 every 2
weeks. Oxaliplatin at 130 mg/m
2 was infused for 2
hours on day 1. Anti-emetics were routinely prescribed,
and granulocyte colony stimulating factor (G-CSF) was
regularly used. Surgery was performed 2-8 weeks after
completion of neoadjuvant therapy, and gastric resection
was completed in a similar fashion for both groups.
Patients received either an en bloc radical proximal, dis-
tal, or total gastrectomy depending on the anatomic
location of the cancer with a view to R0 resection. A D2
lymphadenectomy was performed according to the Japa-
nese Research Society for Gastric Cancer guidelines [5].
Intra-operative frozen sections were used liberally for
confirmation of negative margins. All patients received
the same perioperative management such as prophylac-
tic antibiotics, nutritional support (total parenteral nutri-
tion, TPN), and drainage. Nasogastric tubes were not
routinely used unless there were signs of obstruction.
Demographic, clinical, and pathologic characteristics
of the two groups were analysed. Statistical analysis was
performed with the SPSS 13.0 statistical software. The
comparisons among groups were performed by Stu-
dent’s t test and the chi-square test. P values are
reported for a two-tailed test with P < 0.05 considered
significant.
Results
Patient demographics and Clinical characteristics
Patient demographics and clinical characteristics are
outlined in Table 1. The group included 277 men and
100 women. The median age was 59 years. NACT
patients tended to be younger than SURG patients (56
years vs. 60 years; P = 0.008). NACT patients were
more likely to have proximal tumours with 46% being
located at the gastroesophageal junction/cardia com-
pared to 24% in the SURG group. Conversely, SURG
patients were more likely to have distal lesions (P =
0.000) as reflected by the surgeries performed with 33%
of NACT patients undergoing distal subtotal gastrect-
omy compared with 58% of SURG patients (P = 0.000).
As previously mentioned, all patients had locally
advanced cancers defined as T3 or T4 with or without
nodal involvement as determined by physical examina-
tion, imaging and endoscopy. Although clinical staging
before treatment was similar in the two groups, patholo-
gic staging (according to the AJCC system) showed less
cases of the T (P = 0.000) and N (P = 0.009) stages in
the NACT group as compared with the SURG group,
which is consistent with a tumour downstaging effect.
More than 50% of patients in the NACT group acquired
major response and nearly 30% of patients got experi-
enced tumour downstaging in the T stage.
Preoperative status
The performance status of all patients according to the
Eastern Cooperative Oncology Group was either 0 or 1.
Twenty-four (6%) of all 367 patients had BMI values
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BMI values between the NACT and SURG patients (P =
0.773). The mean preoperative serum albumin was 42.77
g/L in the NACT group and 42.15 g/L in the SURG
group (P = 0.211). There was also no difference in the
preoperative CEA, CA199 or haemoglobin between the
two groups. The white blood cell counts of both groups
were within the normal range, although counts were
lower in the NACT group than in the SURG group (P =
0.000), which is also consistent with a chemotherapy
effect. SURG patients were more likely to have a comor-
bid illness (P = 0.033). Cardiovascular disease with a his-
tory of previous myocardial infarction, ischemic heart
disease, and hypertension requiring treatment was pre-
valent in 16% of NACT patients and 22% of SURG
patients (P = 0.083). There were no significant differ-
ences in the prevalence of diabetes mellitus, pulmonary,
renal, or liver diseases, or surgical histories between the
NACT and SURG patients (Table 2).
A total of 410 cycles of preoperative chemotherapy
were delivered to NACT patients, with a median of four
cycles per patient (ranging from two to six cycles per
patient). Two patients (2%), 14 patients (13%), 5 patients
(5%), 84 patients (76%), 1 patient (1%) and 4 patients
(4%) received one, two, three, four, five or six cycles,
respectively, of chemotherapy before surgery. No dose
reduction was required in the 410 cycles delivered, and
there were no significant differences in the presence of
complications among the patients receiving different
numbers of chemotherapy cycles.
Operative parameters
Mean total operative time (excluding anaesthetic pre-
paration and repositioning of the patient) was 200 min-
utes in the NACT group and 183 minutes in the SURG
group (P = 0.005). Consequences of chemotherapy, such
as tissue oedema, may require increased surgical time
for careful dissection. Mean operative blood loss was
235 mL in the NACT group and 197 mL in the SURG
group (P = 0.061). Perioperative transfusion was com-
pleted in 10% of NACT patients and 17% of SURG
patients (P = 0.063), including those procedures only for
the correction of preoperative anaemia. The NACT
patients had more total/proximal gastrectomies than the
SURG group (P = 0.000). There were no significant dif-
ferences between the two groups in the extent of resec-
tion, multi-visceral resection, type reconstruction or
number of nodes harvested (Table 3). Multi-visceral
resection, including cholecystectomy, splenectomy, par-
tial pancreatectomy, partial colectomy and partial liver
resection, was performed in 9.7% of SURG patients as
compared to 14.5% of NACT patients (P = 0.177).
Complications
Complications occurred in 57 of the 377 patients under-
going resection and were not significantly different
Table 1 Patient demographics and clinical characteristics
NACT (%)
n = 110
SURG (%)
n = 267
P
value
Age, years 55.5 ± 11.5 59.7 ± 12.2 0.008
Median (range) 56.0(26-82) 59(25-85)
Gender 0.576
Male 83(75.5%) 194(72.7%)
Female 27(24.5%) 73(27.3%)
Tumor location 0.000
Proximal 51 (46.4%) 64 (24.0%)
Body 17(15.5%) 40(15.0%)
Distal 41(37.3%) 157(58.8%)
Gastric remnant 0(0%) 2(0.7%)
Other(total) 1(0.9%) 4(1.5%)
Pre-treatment clinical T Staging/Pathological T Staging
-T0 0(0%)/6(5.5%) 0(0%)/0(0%) 0.000
-T1 0(0%)/6(5.5%) 0(0%)/1(0.4%)
-T2 0(0%)/13(11.8%) 0(0%)/28(10.5%)
-T3 90(81.8%)/73
(66.4%)
251(94%)/221
(82.8%)
-T4 20(18.2%)/12
(10.9%)
16(6.0%)/17(6.4%)
Pathological N
Staging
0.009
-N0 34(30.9%) 44(16.5%)
-N1 47(42.7%) 119(44.6%)
-N2 17(15.5%) 65(24.3%)
-N3 12(10.9%) 39(14.6%)
NS = not significant
Table 2 Patient preoperative status
NACT (%)
n = 110
SURG (%)
n = 267
P
value
Body mass index
(BMI)
22.92 ± 3.12 23.03 ± 3.56 0.773
White blood cells 5.29 ± 1.84 6.25 ± 2.10 0.000
Hemoglobin 121.72 ± 21.92 123.93 ± 28.26 0.417
Serum albumin 42.83 ± 4.25 42.18 ± 4.62 0.211
CEA 15.986 ± 67.377 4.357 ± 9.192 0.081
CA199 175.836 ±
803.631
81.270 ±
394.942
0.255
Comorbid illness 44(40.0%) 139(52.1%) 0.033
Cardiovascular 20(18.2%) 71(26.6%) 0.083
Pulmonary 3(2.7%) 9(3.4%) 1.000
Gastric Disease 1(0.9%) 12(4.5%) 0.119
Renal 0(0.0%) 5(1.9%) 0.327
Diabetes mellitus 6(5.5%) 28(10.5%) 0.121
Liver disease 3(2.7%) 10(3.7%) 0.764
Operation history 20(18.2%) 48(18.0%) 0.963
Tuberculosis history 1(0.9%) 3(1.1%) 1.000
Others 7(6.4%) 14(5.2%) 0.666
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all median postoperative hospital stay was 11 days in
the NACT group and 13 days in the SURG group (P =
0.015). For patients with no complications, the median
postoperative stay was 10 days in both groups (P =
0.952), and for those suffering morbidity, median values
were 17 days in the NACT group and 24 days in the
SURG group (P = 0.174).
Overall, nonsurgical complications and surgical com-
plications were similar between the NACT and SURG
groups. The most common nonsurgical complications
were gastric motility disorder and pulmonary problems.
Anastomotic leak and intra-abdominal abscess were the
most common surgical complications in these patients.
Of the 377 patients undergoing radical gastrectomy,
there were two deaths (both in the SURG group, 0.7%),
and ten patients (one in the NACT group) required
early reoperation. Neoadjuvant chemotherapy did not
increase the risk of postoperative complications, mortal-
ity, or the need for reoperation. The two deaths in the
SURG group were the result of multi-organ failure on
day 45 following oesophago-gastric anastomotic leak,
which underwent late re-exploration, and septic compli-
cations on postoperative day 8 related to the abdominal
abscess, respectively. Nine SURG patients underwent re-
exploration. Six were for postoperative leak with one
eventual death, two for postoperative haemorrhage and
one for abdominal abscess. By Multinomial Logistic ana-
lysis, there was no significant association between the
development of complications and the following vari-
ables: age, sex, tumour location, type of resection, extent
of resection (R0), multi-visceral resection, nodal dissec-
tion, pathologic AJCC stage, and whether the patient
received neoadjuvant chemotherapy.
Discussion
The goal of surgery for gastric carcinoma is a curative
resection that involves the removal of all gross cancer
and regional lymph nodes without leaving any macro-
scopically visible cancer lesions. Neoadjuvant che-
motherapy for gastric cancer aims to downstage the
tumour, thus improving the curative resectability of
Table 3 Patient operative parameters
NACT (%)
n = 110
SURG (%)
n = 267
P value
Mean total operative time 200.4 ± 56.6 mins 182.8 ± 53.5 mins 0.005
Mean operative blood loss 235.1 ± 185.3 ml 197.5 ± 149.9 ml 0.061
Patients with transfusion 10 (9.1%) 44(16.5%) 0.063
Type of resection 0.000
Total gastrectomy (via abdomen) 45(40.9%) 66(24.7%)
Total gastrectomy (via abd & cht) 2(1.8%) 0(0%)
Distal gastrectomy 36(32.7%) 156(58.4%)
Proximal gastrectomy (via abd) 24(21.8%) 45(16.9%)
Proximal gastrectomy (via abd & cht) 3(2.7%) 0(0.0%)
Radical resection 0.112
R0 110(100.0%) 260(97.4%)
R1 or R2 0(0%) 7(2.6%)
Multivisceral resection 16(14.5%) 26(9.7%) 0.177
Reconstruction
Total gastrectomy 47(42.7%) 66(24.7%) 1.000
Roux-en-Y 4(8.5%) 6(9.1%)
Jejunal interposition with a r-pouch 43(91.5%) 60(90.9%)
Distal gastrectomy Billroth-I 36(32.7%) 35(97.2%) 156(58.4%) 123(78.8%) 0.074
Billroth-II 1(2.8%) 17(10.9%)
Roux-en-Y 0(0.0%) 15(9.6%)
Jejunal interposition with a r-pouch 0(0.0%) 1(0.6%)
Proximal gastrectomy 27(24.5%) 45(16.9%) 0.238
Esophagogastric anastomosis 26(96.3%) 43(95.6%)
Jejunal interposition with a r-pouch 0(0.0%) 2(4.4%)
Others 1(3.7%) 0(0.0%)
manual anastomosis 3(2.9%) 1(0.4%) 0.072
Median no. of nodes harvested 32.4 ± 14.0 32.3 ± 13.5 0.963
abd: abdomen; cht: chest
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survival of patients. Since the publication of the results
from the MAGIC trial, substantial scientific evidence
has suggested the benefits of perioperative (preoperative
and postoperative) chemotherapy for locally advanced
gastric cancer [3]. Up to this point, many neoadjuvant
chemotherapy treatments for gastric cancer have been
used with varying success to downstage locally advanced
gastric cancers [4], and finding a better regimen of
choice for neoadjuvant chemotherapy is undoubtedly
the focus of this area. However, there are limited data
available regarding postoperative morbidity and mortal-
ity in patients receiving neoadjuvant chemotherapy of
different regimens for gastric cancer, and most studies
providing detailed analysis of postoperative complica-
tions in patients receiving neoadjuvant chemotherapy
have not included a comparative group of patients
undergoing surgery alone [6-8]. It is necessary to assess
the influence of preoperative chemotherapy on surgery
if it is to be considered as a standard treatment, espe-
cially with the increasing number of new drugs available
for clinical application. Clinical trials concerning neoad-
juvant therapy with the FOLFOX regimen for local
advanced gastric cancer have been performed in our
department since 2002. This retrospective study aimed
to examine postoperative morbidity and mortality in
patients receiving neoadjuvant FOLFOX7 chemotherapy
compared to a group of patients undergoing surgical
resection only during the same time frame and by the
same surgeons. The results indicated that Oxaliplatin-
based neoadjuvant chemotherapy does not increase the
risk of postoperative complications in patients under-
going gastrectomy with D2 lymphadenectomy for gastric
cancer.
Surgical morbidity and mortality following gastrect-
omy can be substantial. The most frequent complica-
tions following gastrectomy for gastric cancer are
pulmonary problems, anastomotic leakage, intra-abdom-
inal abscess, and wound infection[9-12]. Factors
reported to influence morbidity in patients undergoing
gastrectomy for gastric cancer include multi-organ
resection, especially splenectomy and distal pancreatect-
omy, age greater than 70 years with underlying cardio-
pulmonary or renal disease, and extended lymph node
dissection. In patients with gastric cancer receiving
neoadjuvant chemotherapy followed by resection, post-
operative morbidity ranges from 23% to 40% and mor-
tality from 0% to 10% [6-8,13-17]. These figures are
similar to reports of morbidity and mortality in patients
undergoing gastric resection without neoadjuvant che-
motherapy [9-12,18-23] and are similar to findings in
our study, which also support the observation that
neoadjuvant chemotherapy does not increase morbidity
and mortality. In the current study, morbidity was 10.9%
in the NACT patients and 17.2% in the SURG patients.
There were two postoperative deaths, both in the SURG
Table 4 Morbidity and mortality
NACT (%)
n = 110
SURG (%)
n = 267
P value
Patients with complications 11(10.0%) 46(17.2%) 0.075
Postoperative LOS (days) 11.0 ± 4.7(5-40) 13 ± 8.9(6-79) 0.015
Postoperative LOS with complications (days) 16.8 ± 10.9(7-40) 24.0 ± 16.4(6-79) 0.174
Postoperative LOS without complications (days) 10.4 ± 2.8(5-19) 10.4 ± 3.1(6-27) 0.952
Nonsurgical complications
Pneumonia 1(0.9%) 4(1.5%) 1.000
Pleural effusion 2(1.8%) 2(0.7%) 0.583
gastric motility disorder 2(1.8%) 10(3.7%) 0.521
Mental status changes 0(0.0%) 1(0.4%) 1.000
Others (Diarrhea, Hiccup, 0(0.0%) 4(1.5%) 0.326
Thrombocytopenia) No. of patients 4(3.6%) 21(7.9%) 0.134
Surgical complications
Anastomotic leak 2(1.8%) 9(3.4%) 0.520
Intra-abdominal abscess 3(2.7%) 8(3.0%) 1.000
Postoperative bowel obstruction/ileus 2(1.8%) 3(1.1%) 0.631
Postoperative hemorrhage 0(0.0%) 4(1.5%) 0.326
Wound infection 0(0.0%) 2(0.7%) 1.000
No. of patients 7(6.4%) 26(9.7%) 0.292
Reexploration 1(0.9%) 9(3.4%) 0.292
Mortality 0(0.0%) 2(0.7%) 1.000
LOS = length of stay; NS = not significant
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be associated with the development of complications.
Only 24 (6%) patients with BMI values greater than 28
were included in our study, reflecting the differences
between patients populations in the East and West and
potentially explaining the lower incidence of morbidity
and mortality in the Eastern study. Although the SURG
patients were older (P = 0.008), increasing age was not
associated with the development of postoperative com-
plications and may be associated with the longer post-
operative hospital stay (P = 0.015). Both groups of
patients had similar pre-treatment cancer stages. We
believe that the preponderance of lower numbers of T
and N stages in the NACT group as opposed to those
in the SURG group are the result of the downstaging
effect following neoadjuvant chemotherapy.
Although D2 lymphadenectomy was routinely per-
formed in our patients, multi-visceral resection, espe-
cially distal pancreatectomy and splenectomy, was rarely
necessary. Others have reported increasing age and
extended lymphadenopathy with multi-visceral resection
to be associated with increasing mortality [10,12,21]. We
agree that extended lymphadenectomy combined with
multi-visceral resection, specifically splenectomy with or
without distal pancreatectomy, should be avoided unless
there is direct extension of the tumour mandating resec-
tion to achieve negative margins [20,24]. The low rate of
major surgical complications and mortality secondary to
surgical complications in the current cohort may be par-
tially related to our limited use of multi-visceral
resection.
Re-laparotomy for complications of gastrectomy is
necessary in 2% to 12% of cases [9,12,19-21]. In a large
series of 700 gastrectomies reported by Shchepotin et
al., 40 patients (5.7%) underwent reoperation with an
associated mortality of 62.5%. Anastomotic leakage and
pancreatic necrosis were the most common indications
for reoperation. Ten patients in the current series,
including six patients with leak, underwent re-explora-
tion. Postoperative pancreatitis was not observed in our
series. With improved surgical techniques, anastomotic
leaks appear to be decreasing in incidence. We agree
with the opinion that leaks should be managed conser-
vatively and reoperation reserved for patients in whom
conservative management is unsuccessful [23]. In the
current series, two patients in the SURG group who
underwent reoperation died. Operative mortality rates
following gastrectomy range from 0% to 10%
[6-8,13-17]. Our overall postoperative mortality of 0.7%
is within this range, and FOLFOX7 neoadjuvant che-
motherapy was not associated with an increase in mor-
tality, which is consistent with results in other series in
which various regimens of neoadjuvant chemotherapy
were used [6,8,14,15,25].
Conclusions
One of the theoretical advantages of neoadjuvant ther-
apy is the enhanced ability to deliver multimodality
therapy to all suitable patients and not delay a patient’s
therapy because of a prolonged recovery from surgery
or inadequate resection. In summary, we have shown
that neoadjuvant chemotherapy with FOLFOX7 can be
delivered without increasing surgical morbidity and
mortality compared to gastrectomy alone. In this
respect, neoadjuvant chemotherapy with FOLFOX7 is a
safe candidate for the treatment of local advanced gas-
tric cancer. However, this is a retrospective study from a
single centre, and future studies are needed to confirm
these results. In China, a randomised multicentre phase
III study conducted by our centre is underway to evalu-
ate the effectiveness of neoadjuvant chemotherapy with
the FOLFOX regimen for locally advanced gastric can-
cer. Further investigation is warranted to determine the
most efficacious and least toxic combination regimen of
neoadjuvant/adjuvant therapies for treating gastric
cancer.
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